Heart attack gene, MRP-14, triggers blood clot formation

April 1, 2014
The blood clot, or thrombus, was extracted from a heart attack patient's cardiac artery and stained for MRP-14 and platelets. This slide image shows that platelets are loaded with MRP-14, and those appear as yellow areas. Credit: Journal of Clinical Investigation: Adapted from Figure 8:H in "Platelet-Derived Myeloid Related Protein-14 (S100A9) Regulates Thrombosis

Right now, options are limited for preventing heart attacks. However, the day may come when treatments target the heart attack gene, myeloid related protein-14 (MRP-14, also known as S100A9) and defang its ability to produce heart attack-inducing blood clots, a process referred to as thrombosis.

Scientists at Case Western Reserve School of Medicine and University Hospitals Case Medical Center have reached a groundbreaking milestone toward this goal. They have studied humans and mice and discovered how MRP-14 generates dangerous clots that could trigger or stroke, and what happens by manipulating MRP-14. This study describes a previously unrecognized platelet-dependent pathway of thrombosis. The results of this research will appear in the April edition of the Journal for Clinical Investigation (JCI).

"This is exciting because we have now closed the loop of our original finding that MRP-14 is a heart attack gene," said Daniel I. Simon, MD, the Herman K. Hellerstein Professor of Cardiovascular Research and Medicine at the School of Medicine and director of the University Hospitals Harrington Heart & Vascular Institute. "We now describe a whole new pathway that shows clotting platelets have MRP-14 inside them, that platelets secrete MRP-14 and that MRP-14 binds to a platelet receptor called CD36 to activate platelets."

This translational research has moved back and forth from the cardiac catheterization laboratory investigating patients presenting with heart attack to the basic research lab probing mechanisms of disease. The clinical portion of this research yielded a visually stunning element— extracted from an occluded heart artery loaded with MRP-14 containing platelets.

"It is remarkable that this abundant platelet protein promoting thrombosis could have gone undetected until now," Simon said.

In detailed studies using MRP-14-deficient mice, the investigators discovered MRP-14 in action. One key finding is that, while MRP-14 is required for pathologic blood clotting, it does not appear to be involved in the natural, primary hemostasis response to prevent bleeding.

"The practical significance of this research is that it may provide a new target to develop more effective and safer anti-thrombotic agents," Simon said. Current anti-clotting drugs are subject to significant bleeding risk, which is associated with increased mortality.

"If we could develop an agent that affects pathologic clotting and not hemostasis, that would be a home run," Simon said. "You would have a safer medication to treat pathologic clotting in heart attack and stroke."

Explore further: Blood cell breakthrough could help treat heart disease

Related Stories

Blood cell breakthrough could help treat heart disease

April 27, 2012

(Phys.org) -- Scientists at the University of Reading have made a groundbreaking discovery into the way blood clots are formed, potentially leading to the development of new drugs to treat one of the world's biggest killer ...

Researchers find key to blood-clotting process

June 26, 2013

Researchers, including Professor Alastair Poole and Dr Matthew Harper from the University of Bristol's School of Physiology and Pharmacology, have uncovered a key process in understanding how blood clots form that could help ...

Blood cell breakthrough could help save lives

October 8, 2013

Cutting-edge research from the University of Reading has provided a crucial breakthrough in understanding how blood clots form. The results of the study, funded by the British Heart Foundation (BHF), could potentially lead ...

Heart attack drug proven to have no rebound effect

February 3, 2014

(Medical Xpress)—Clopidogrel, a drug prescribed to thousands of people who have had a heart attack, can be safely withdrawn with no 'rebound effect', according to a study by Aberdeen scientists.

Recommended for you

Competing mice reveal genetic defects

September 30, 2015

In recent years, University of Utah biologists showed that when wild-type mice compete in seminatural "mouse barns" for food, territory and mates, they can suffer health problems not revealed by conventional toxicity tests ...

Maintaining healthy DNA delays menopause

September 28, 2015

An international study of nearly 70,000 women has identified more than forty regions of the human genome that are involved in governing at what age a woman goes through the menopause. The study, led by scientists at the Universities ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.